rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Liminatus Pharma, Inc.

LIMN · Nasdaq

Health CareBiotechnologyNot moving yet

LIMN stood above a rising 150-day average in 0 of the last 42 weekly readings. It is 55.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 42
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
13 (+0)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 42 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders13+0 on the quarter
New · exited4 · 4
Reported value$69K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
XTX Topco Ltdnew · filed 14 Aug 2026221,839$24K+221,839
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026138,418$15K+20,635+17.5%
CITADEL ADVISORS LLCreduced · filed 14 Aug 202656,089$6,192-621,429−91.7%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 202650,440$5,54800.0%
GOLDMAN SACHS GROUP INCnew · filed 14 Aug 202640,220$4,440+40,220
StoneX Group Inc.new · filed 12 Aug 202626,058$3,934+26,058
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202622,984$2,52800.0%
STATE STREET CORPunchanged · filed 7 Aug 202619,000$2,09800.0%
UBS Group AGreduced · filed 13 Aug 202616,730$1,840-37,848−69.3%
Vanguard Personalized Indexing Management, LLCreduced · filed 11 Aug 202613,148$1,452-21,558−62.1%
30 Jun 2025 – 30 Jun 2026
91113Jun 25Sep 25Dec 25Mar 26Jun 26

News

No headline names it lately.

Everyone who traded it

Valetudo Therapeutics LLC Company insider10% owner · last 2 Jul 20260 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 27 Mar 202665.8%
Free cash flowFY 2025 · to 31 Dec 2025−$10.0M

Analyst forecasts

No analyst forecasts yet.